On this news, the Company's share price declined from $33.45 on July 26, 2017, to $32.10 on July 27, 2017 - a $1.35 or a 4.04% drop.Then, on October 30, 2017, Omega announced its third quarter 2017 financial results. The next day, the Company held a conference call to discuss its results, wherein Daniel Booth disclosed that the Company "[continued] to experience specific operator performance issues" in addition to issues with Signature Healthcare, due to "liquidity issues [that] are impacting the ability of these operators to pay rent on a timely basis." During the same call, Robert Stephenson, the Company's Chief Financial Officer, stated that the Company's decrease in operating revenue "was primarily a result of placing Orianna on a cash basis." Following the announcement, Omega's share price fell from $30.97 per share on October 30, 2017 to a closing price of $28.86 on October 31, 2017 - a $2.11 or a 6.81% drop. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Omega's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.